Inspiremd (NSPR) closed at $0.77 on November 12, 2026, down 3.3% from the previous close, on volume of 159,222 shares (30-day average 286,784).
Data as of November 12, 2026.
InspireMD FDA Approves CGuard Prime for TCAR Procedures
TipRanks (Thu, 12-Nov 5:59 PM ET)
InspireMD FDA Approves CGuard Prime, Restoring U.S. Market Access
TipRanks (Thu, 12-Nov 5:59 PM ET)
InspireMD announces proposed public offering
Seeking Alpha News (Thu, 12-Nov 4:24 PM ET)
InspireMD Announces Proposed Public Offering
Globe Newswire (Thu, 12-Nov 4:15 PM ET)
InspireMD Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 12-Nov 4:03 PM ET)
Globe Newswire (Thu, 12-Nov 4:01 PM ET)
Here are the major earnings before the open Thursday
Seeking Alpha News (Wed, 11-Nov 6:00 PM ET)
InspireMD Announces Updated Timing for Third Quarter 2026 Financial Results
Globe Newswire (Wed, 11-Nov 4:05 PM ET)
InspireMD Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 11-Nov 10:45 AM ET)
InspireMD to Announce Third Quarter 2026 Financial Results
Globe Newswire (Thu, 29-Oct 8:00 AM ET)
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Inspiremd trades on the NASDAQ stock market under the symbol NSPR.
As of November 12, 2026, NSPR stock price declined to $0.77 with 159,222 million shares trading.
NSPR has a beta of -0.29, meaning it tends to be less sensitive to market movements. NSPR has a correlation of 0.00 to the broad based SPY ETF.
NSPR has a market cap of $36.25 million. This is considered a Sub-Micro Cap stock.
Last quarter Inspiremd reported $2 million in Revenue and -$.17 earnings per share. This beat revenue expectation by $334,600 and exceeded earnings estimates by $.03.
In the last 3 years, NSPR traded as high as $3.80 and as low as $.43.
The top ETF exchange traded funds that NSPR belongs to (by Net Assets): IWC.
NSPR has underperformed the market in the last year with a return of -52.5%, while the SPY ETF gained +12.0%. In the last 3 month period, NSPR fell short of the market, returning -9.2%, while SPY returned -1.5%. However, in the most recent 2 weeks NSPR has outperformed the stock market by returning +65.4%, while SPY returned -2.0%.
NSPR support price is $.72 and resistance is $.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NSPR shares will trade within this expected range on the day.